Pages that link to "Q36709839"
Jump to navigation
Jump to search
The following pages link to P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse (Q36709839):
Displaying 50 items.
- The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia (Q26775506) (← links)
- Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia (Q26779129) (← links)
- PI3K isoform-selective inhibitors: next-generation targeted cancer therapies (Q26781294) (← links)
- PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL) (Q26782633) (← links)
- Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma (Q26865645) (← links)
- Targeted therapies in CLL: mechanisms of resistance and strategies for management (Q27002528) (← links)
- Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma (Q27026544) (← links)
- Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy (Q29248893) (← links)
- PI3K and cancer: lessons, challenges and opportunities (Q30080017) (← links)
- The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date (Q31070331) (← links)
- Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies (Q33558141) (← links)
- PIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro (Q33602560) (← links)
- Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. (Q33779805) (← links)
- Do mantle cell lymphomas have an 'Achilles heel'? (Q34095009) (← links)
- Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma (Q34255861) (← links)
- Idelalisib in the management of lymphoma. (Q34529311) (← links)
- A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). (Q34663617) (← links)
- Identifying molecular features associated with psychoneurological symptoms in women with breast cancer using multivariate mixed models. (Q35591916) (← links)
- Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas (Q36436997) (← links)
- Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth (Q36445743) (← links)
- PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition (Q36899519) (← links)
- Targeted therapy in chronic lymphocytic leukemia: past, present, and future (Q37430243) (← links)
- B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities (Q38124119) (← links)
- Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. (Q38237619) (← links)
- Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma (Q38373698) (← links)
- Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide (Q38863364) (← links)
- B-cell receptor pathway modulators in NHL. (Q38686328) (← links)
- Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon? (Q38675161) (← links)
- Targeting of B-cell receptor signalling in B-cell malignancies. (Q38744922) (← links)
- Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells (Q38882332) (← links)
- Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. (Q38957093) (← links)
- Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease (Q39034465) (← links)
- Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. (Q39151631) (← links)
- Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia (Q39169789) (← links)
- The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. (Q40575812) (← links)
- PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma (Q41994564) (← links)
- Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy (Q42578145) (← links)
- The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells (Q42924738) (← links)
- Putative roles for PI3K α and δ isoforms in refractory mantle cell lymphoma (Q46897889) (← links)
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma (Q47169310) (← links)
- Revival of PI3K inhibitors in non-Hodgkin's lymphoma (Q50088500) (← links)
- Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma (Q51682819) (← links)
- Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. (Q52725994) (← links)
- Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly (Q54316519) (← links)
- Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib (Q58729853) (← links)
- [Advances of aberrant signaling pathways and related targeting drugs in B cell non- Hodgkin lymphoma] (Q87063062) (← links)
- Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma (Q89467484) (← links)
- Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma? (Q89599313) (← links)
- Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion (Q89666580) (← links)
- Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models (Q89998348) (← links)